AstraZeneca and CRT to develop cancer metabolism targeted therapies
This article was originally published in Scrip
Executive Summary
Cancer Research Technology (CRT) will collaborate with AstraZeneca to create a slate of new anticancer therapies over the next three years. CRT, the commercial and development arm of Cancer Research UK, will select the candidates for use in the field of cancer metabolism.